Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192106 | 0.83 | HPGD (0.49) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL10192167 | 0.81 | CA1 (0.48) | MAPTHPGDKMT2AMEN1LMNA | |
| SCHEMBL7835580 | 0.81 | CA2 (0.45) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6936465 | 0.80 | HPGD (0.51) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL14582129 | 0.78 | NPSR1 (0.57) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL10192105 | 0.78 | HPGD (0.53) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL10191948 | 0.76 | HPGD (0.46) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL23901543 | 0.76 | RECQL (0.58) | CYP3A4CYP1A2ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL10996020 | 0.75 | MAPT (0.77) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL10191952 | 0.74 | HPGD (0.53) | HTTCYP3A4CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HTT 3355/4885CYP3A4 2507/4885CYP2C9 3797/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HTT 3147/4885CYP3A4 3086/4885CYP2C9 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.